Ambroxol is an already approved medicine in the treatment of coughs. However, it was discovered that ambroxol increased the activity of the GCase enzyme, which is made by the GBA gene. This is enzyme is believed to have a role in Parkinson’s. Some individuals who have Parkinson’s may carry one copy of a faulty GBA gene, reducing the activity of the GCase enzyme.
Professor Schapira led the Phase 2 clinical trial for ambroxol, named AIM-PD from 2017-2018. Though the study was small, AIM-PD proved promising in that the results indicated that GCase levels increased. To learn more, please visit the Cure Parkinson's Website.
Professor Schapira and his team are now keen to test the effectiveness of ambroxol in a Phase III clinical trial. We are looking for those who have Parkinson’s Disease, whether they know if they have a faulty GBA gene. Please refer to the 'Taking Part in Ambroxol' box below to see if you are eligible. Learn more by clicking here.
To take part in the trial you must be aged 35-75 and diagnosed within the last 6 years.
Taking Part in Ambroxol
Please select your health status.
After which you will be asked to regsiter for Rapsodi or PD-Frontline where you can then express your interest in the Ambroxol trial.
Unfortunately, you are not eligible to take part
Please register of the Rapsodi study where you can express your interest in this trial
Register to Rapsodi
Please register of the PD-Frontline study where you can express your interest in this trial
Register to PD-Frontline